Evotec stock gains 1.1% from latest report ahead of results
Published on 11/03/2026 at 18:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat is moving Evotec stock
- Evotec stock has moved higher since the latest report, while the company approaches its next scheduled results update.
- Investors remain focused on the companys recovery path, analyst expectations and the outlook for profitability.
Evotec stock traded at 2.85 euros on Lang & Schwarz at 18:28 CET on Tuesday, November 3, 2026. That was 1.06 percent above the 2.82-euro quote recorded in the latest report at 11:52 CET the same day. The real-time quote of Evotec stock shows the latest trading level.
Analyst caution meets recovery hopes
The latest company coverage highlighted a sharp split in the investment case. RBC Capital Markets retained an Outperform rating but cut its price target from 10 euros to 5 euros and added a Speculative Risk designation.
The lower target reflects a more cautious valuation view rather than a change in the banks stated direction. RBC analyst Charles Weston nevertheless expects substantially lower losses in 2027 and significant profitability in 2028, according to the cited assessment. Those expectations remain analyst forecasts, not company guidance.
Results remain the next test
Evotec is scheduled to publish its third-quarter and first-nine-month results for 2026 on Thursday, November 5, together with a business update. The previous report cited preliminary nine-month revenue of 465.0 million euros and adjusted group EBITDA of negative 42.8 million euros, alongside reaffirmed 2026 revenue guidance of 570 million to 610 million euros and adjusted EBITDA guidance of negative 70 million to negative 105 million euros.
Evotecs investor-relations materials describe a business focused on drug discovery, development and manufacturing partnerships, with Just - Evotec Biologics positioned as a growth platform.
Evotec SE at a glance
- Company: Evotec SE
- ISIN: DE0005664809
- Trading venue: Lang & Schwarz
- Price: 2.85 euros at 18:28 CET on November 3, 2026
- Change since latest report: 1.06 percent from 2.82 euros at 11:52 CET
The German market environment, tracked through the DAX, remains the broader backdrop for Evotecs next trading sessions.
Further operating detail is expected with the results and business update. See More news and analyses on Evotec stock.
